An open-label, prospective, randomized, three-way crossove study comparing pharmacokinetics, safety and tolerability of DFN-02 with intranasal sumatriptan in healthy volunteers

Trial Profile

An open-label, prospective, randomized, three-way crossove study comparing pharmacokinetics, safety and tolerability of DFN-02 with intranasal sumatriptan in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs DFN 02 (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 11 Jun 2017 Results presented at the 59th Annual Scientific Meeting of the American Headache Society
    • 27 Sep 2016 New trial record
    • 10 Sep 2016 Results of pooled analysis of effect of permeation enhancer on pharmacokinetics of sumatriptan from this and another trial (CTP 700276438) published in the Headache.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top